Head-to-head · free

Twist Bioscience vs U.S. Physical Therapy

TWST vs USPH — return on capital, cash generation, margins and balance sheet side by side.

TWST

1 / 5

measures where TWST leads

USPH

4 / 5

measures where USPH leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTWST · FY2026USPH · FY2025
Revenue—$781.0M
Net income(130.2M)$39.6M
Revenue growth (yearly, multi-year)—12.1%
Free cash flow(89.0M)—
Free cash flow margin——
Net cash / (debt)——
ROIC—6.0%
Return on equity-16.4%3.1%
Gross margin50.7%19.2%
Operating margin-36.2%10.3%
Net debt / EBITDA1.64x1.16x

Figures are as reported by each company; latest fiscal year shown.

Where Twist Bioscience's cash went (FY2026)

Capital spending
$47.6M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TWST profile →

Where U.S. Physical Therapy's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full USPH profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons